Article
Hematology
Niklas Gebauer, Hanno M. Witte, Hartmut Merz, Ilske Oschlies, Wolfram Klapper, Almuth Caliebe, Lars Tharun, Malte Spielmann, Nikolas von Bubnoff, Alfred C. Feller, Eva M. Murga Penas
Summary: A recent discovery of Burkitt-like lymphoma with 11q aberration (BLL-11q) suggests that 11q abnormalities can be found in both BLL in the context of an underlying HIV infection and in high-grade B-cell lymphomas with MYC, BCL2, and/or BCL6 rearrangements. This indicates that the clinicopathological spectrum of malignancies carrying this aberration may be broader than previously assumed.
Article
Hematology
Anne C. Wilke, Carmen Doebele, Alena Zindel, Kwang Seok Lee, Sara A. Rieke, Michele Ceribelli, Federico Comoglio, James D. Phelan, James Q. Wang, Yana Pikman, Dominique Jahn, Bjoern Haeupl, Constanze Schneider, Sebastian Scheich, Frances A. Tosto, Hanibal Bohnenberger, Philipp Stauder, Frank Schnuetgen, Mikolaj Slabicki, Zana A. Coulibaly, Sebastian Wolf, Kamil Bojarczuk, Bjoern Chapuy, Christian H. Brandts, Philipp Stroebel, Caroline A. Lewis, Michael Engelke, Xincheng Xu, Hahn Kim, Thanh Hung Dang, Roland Schmitz, Daniel J. Hodson, Kimberly Stegmaier, Henning Urlaub, Hubert Serve, Clemens A. Schmitt, Fernando Kreuz, Gero Knittel, Joshua D. Rabinowitz, Hans Christian Reinhardt, Matthew G. Vander Heiden, Craig Thomas, Louis M. Staudt, Thorsten Zenz, Thomas Oellerich
Summary: This study identified vulnerabilities in Burkitt lymphoma (BL) through genome-scale CRISPR-Cas9 screens and validated serine hydroxymethyltransferase 2 (SHMT2) as a potential drug target. Mechanistically, SHMT2 inhibition disrupted the oncogenic transcription factor TCF3 and collapsed tonic BCR signaling, providing new perspectives for innovative therapies.
Article
Multidisciplinary Sciences
Birgit Burkhardt, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp Berning, Katrin Reutter, Marius Rohde, Arndt Borkhardt, Thomas Burmeister, Sandeep Dave, Alexandar Tzankov, Martin Dugas, Sarah Sandmann, Falko Fend, Jasmin Finger, Stephanie Mueller, Nicola Goekbuget, Torsten Haferlach, Wolfgang Kern, Wolfgang Hartmann, Wolfram Klapper, Ilske Oschlies, Julia Richter, Udo Kontny, Mathias Lutz, Britta Maecker-Kolhoff, German Ott, Andreas Rosenwald, Reiner Siebert, Arend von Stackelberg, Brigitte Strahm, Wilhelm Woessmann, Martin Zimmermann, Myroslav Zapukhlyak, Michael Grau, Georg Lenz
Summary: This study compares mutational profiles in different age groups of Burkitt lymphoma patients and finds a transition in mutational features between the ages of 25 and 40. There are also differences in the mutation frequencies between pediatric and adult patients. TP53 mutations in pediatric patients are significantly associated with higher relapse incidence.
NATURE COMMUNICATIONS
(2022)
Article
Veterinary Sciences
Luca Aresu, Chiara Agnoli, Arturo Nicoletti, Antonella Fanelli, Valeria Martini, Francesco Bertoni, Laura Marconato
Summary: Canine Burkitt-like lymphoma (B-LL) is a rare tumor in dogs classified as a high-grade B-cell malignancy. Compared to the human counterpart, phenotypical differences are observed, and despite treatment, prognosis remains poor. However, around 30% of dogs can survive more than 1 year.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Biochemistry & Molecular Biology
Ester Molina, Lucia Garcia-Gutierrez, Vanessa Junco, Mercedes Perez-Olivares, Virginia G. de Yebenes, Rosa Blanco, Laura Quevedo, Juan C. Acosta, Ana V. Marin, Daniela Ulgiati, Ramon Merino, M. Dolores Delgado, Ignacio Varela, Jose R. Regueiro, Ignacio Moreno de Alboran, Almudena R. Ramiro, Javier Leon
Summary: The researchers discovered that the oncogenic transcription factor MYC directly targets the EBV receptor CR2 gene, proposing an alternative hypothesis to the widely accepted mechanism of EBV infection.
Review
Oncology
Coen J. Lap, Samah Nassereddine, Kieron Dunleavy
Summary: Burkitt lymphoma (BL) has a high cure rate, and prompt treatment initiation is crucial for optimal outcomes. Recent studies have focused on reduced intensity therapies with fewer toxic complications to improve tolerability. New molecular insights in BL biology may lead to future targeted therapy approaches.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Shaymaa Elgaafary, Cristina Lopez, Inga Nagel, Inga Vater, Susanne Bens, Monika Szczepanowski, Sietse M. Aukema, Rabea Wagener, Lydia Hopp, Hans Binder, Laurence de Leval, Wolfram Klapper, Reiner Siebert
Summary: Breast and ovarian Burkitt lymphoma (BL) are described as rare but typical in females, especially after puberty. Molecular features of breast and ovarian BL resemble those of BL at other sites, affecting women in fertile age.
LEUKEMIA & LYMPHOMA
(2021)
Editorial Material
Hematology
Mark Roschewski
Summary: This study highlights critical prognostic factors that impact outcomes in adult patients with Burkitt lymphoma in the United States.
Article
Oncology
Semjon Sidorov, Lara Fux, Katja Steiner, Samyo Bounlom, Sabrina Traxel, Tarik Azzi, Arbeneshe Berisha, Christoph Berger, Michele Bernasconi, Felix K. Niggli, Yvonne Perner, Sugeshnee Pather, Werner Kempf, David Nadal, Simone Burgler
Summary: The study reveals the dichotomous effects of CD4 + T cells in endemic Burkitt lymphoma, suggesting that they may suppress cancer development by killing pre-cancerous cells without specific translocations, but also indirectly promote cancer progression by inducing EBV latency switching. Moreover, it demonstrates how CD4 + T cells can impact cancer pathogenesis and progression, providing a new in vitro model for further research on the role of IgH/c-myc translocations.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Ekaterina Mikhailovna Stasevich, Aksinya Nicolaevna Uvarova, Matvey Mikhailovich Murashko, Elmira Ramilevna Khabusheva, Saveliy Andreevich Sheetikov, Vladimir Sergeyevich Prassolov, Dmitriy Vladimirovich Kuprash, Denis Eriksonovich Demin, Anton Markovich Schwartz
Summary: Chromosomal rearrangements, such as the transfer of proto-oncogenes to active transcription regions, are common in various tumors. In Burkitt lymphoma, the IGH/MYC translocation results in increased expression of the MYC proto-oncogene. This study identifies an eRNA, AL928768.3, located at the IGH locus and predominantly expressed in B cells, which plays an important role in Burkitt lymphoma development. Knockdown of AL928768.3 decreases lymphoma cell proliferation and chemotherapy resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Melanie Winkle, Mina M. Tayari, Klaas Kok, Gerben Duns, Natalia Grot, Marta Kazimierska, Annika Seitz, Debora Jong, Jasper Koerts, Arjan Diepstra, Agnieszka Dzikiewicz-Krawczyk, Christian Steidl, Joost Kluiver, Anke van den Berg
Summary: This study identified several Myc-induced and Myc-repressed lncRNAs, and found that one of them, KTN1-AS1, plays a critical role in B cell lymphoma. By mediating co-regulation of multiple Myc-target genes and activating key genes involved in cholesterol biosynthesis, KTN1-AS1 supports the growth of lymphoma cells. Therefore, KTN1-AS1 may represent a potential novel therapeutic target in lymphoma.
HUMAN MOLECULAR GENETICS
(2022)
Article
Multidisciplinary Sciences
Amin Allahyar, Mark Pieterse, Joost Swennenhuis, G. Tjitske Los-de Vries, Mehmet Yilmaz, Roos Leguit, Ruud W. J. Meijers, Robert van der Geize, Joost Vermaat, Arjen Cleven, Tom van Wezel, Arjan Diepstra, Leon C. van Kempen, Nathalie J. Hijmering, Phylicia Stathi, Milan Sharma, Adrien S. J. Melquiond, Paula J. P. de Vree, Marjon J. A. M. Verstegen, Peter H. L. Krijger, Karima Hajo, Marieke Simonis, Agata Rakszewska, Max van Min, Daphne de Jong, Bauke Ylstra, Harma Feitsma, Erik Splinter, Wouter de Laat
Summary: The authors introduced a new method for detecting translocations in preserved samples, which showed high sensitivity and specificity, outperforming traditional methods; FFPE-TLC is a powerful clinical tool for accurate rearrangement detection in FFPE specimens.
NATURE COMMUNICATIONS
(2021)
Article
Plant Sciences
Hui-Min Zhao, Jing He, Yung-Ting Chang, Li-Yun Liu, Fan Sun, Hou-Wen Lin, Fan Yang
Summary: AP-51 has shown potential as a treatment for Burkitt's lymphoma by regulating the cell cycle, inducing apoptosis, causing mitochondrial dysfunction, and inhibiting the PI3K/AKT/mTOR signaling pathway.
JOURNAL OF NATURAL PRODUCTS
(2022)
Article
Pathology
Heike Horn, Sabrina Kalmbach, Rabea Wagener, Annette M. Staiger, Katrin Huttl, Anja Mottok, Susanne Bens, Alexandra Traverse-Glehen, Juliette Fontaine, Reiner Siebert, Andreas Rosenwald, German Ott
Summary: Analysis of 11q status is recommended for MYC-negative high-grade lymphomas with features of Burkitt lymphoma, especially showing BCL2 negativity and a conspicuous coarse apoptotic debris in starry sky macrophages.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2021)
Article
Oncology
Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst
Summary: 20-40% of Burkitt lymphoma (BL) patients have relapsing or refractory (r/r) disease, and the standard treatment is not well-established. Blinatumomab, a bispecific T-cell engager, may be a potential treatment option for these patients. This retrospective multi-center case series investigated the use of blinatumomab in nine r/r BL patients, and found that it was safe and showed activity in some patients. This suggests that blinatumomab should be further explored as a treatment option for r/r BL.
Article
Hematology
Fanbi Meng, Shuang Chen, Chunliang Liu, Muhammad Shoaib Khan, Yan Yan, Jun Wan, Yue Xia, Chenglin Sun, Mengnan Yang, Renping Hu, Kesheng Dai
Summary: PKC plays a critical role in regulating megakaryocyte development and platelet production in thrombocytopenia. The inhibition of PKC activation delays and reduces radiation-induced megakaryocyte apoptosis, leading to improved platelet count recovery. This study provides a potential therapeutic target for treating thrombocytopenia.
BLOOD CELLS MOLECULES AND DISEASES
(2024)
Article
Hematology
Xia Chen, Fang Liu, Yuanyuan Ren, Luyang Zhang, Yang Wan, Wenyu Yang, Xiaojuan Chen, Li Zhang, Yao Zou, Yumei Chen, Xiaofan Zhu, Ye Guo
Summary: Unrelated umbilical cord blood transplantation (UCBT) is an effective alternative treatment for pediatric patients with bone marrow failure. The use of the TBI/BU + FLU + CY conditioning regimen ensures a high engraftment rate for UCBT and overcomes the challenge of graft failure. Secondary salvage use of cord blood transplantation may still be useful for patients who have failed after other transplantation.
BLOOD CELLS MOLECULES AND DISEASES
(2024)
Article
Hematology
Chithra D. Palani, Xingguo Zhu, Manickam Alagar, Otis C. Attucks, Betty S. Pace
Summary: This study evaluated the ability of a novel Bach1 inhibitor, HPP-D, to induce HbF in KU812 cells and primary sickle erythroid progenitors. The results showed that HPP-D increased HbF levels and decreased Bach1 protein levels in both cell types. Furthermore, it enhanced NRF2 binding to the gamma-globin promoter antioxidant response elements, leading to an open chromatin configuration and increased gamma-globin transcription.
BLOOD CELLS MOLECULES AND DISEASES
(2024)
Letter
Hematology
Marcos Borato Viana, Erica Louback Oliveira, Andre Rolim Belisario
BLOOD CELLS MOLECULES AND DISEASES
(2024)
Article
Hematology
Ke Zhang, Longying Ye, Yanhui Jin, Yuan Chen, Shuting Jiang, Haixiao Xie, Lihong Yang, Mingshan Wang
Summary: This study investigated two pedigrees with FV deficiency and identified three mutations that may have deleterious effects on the function and structure of FV.
BLOOD CELLS MOLECULES AND DISEASES
(2024)
